삼성서울병원

Ko En

Sun, Jong Mu M.D

TITLE
Clinical Associate Professor, Division of Hem/Oncology, Samsung Medical Center
Treament Schedule 04 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
AM
PM
Treament Schedule 05 月
DATE
FRI
01
SAT
02
SUN
03
MON
04
TUE
05
WEB
06
THU
07
FRI
08
SAT
09
SUN
10
MON
11
TUE
12
WEB
13
THU
14
FRI
15
SAT
16
SUN
17
MON
18
TUE
19
WEB
20
THU
21
FRI
22
SAT
23
SUN
24
MON
25
TUE
26
WEB
27
THU
28
FRI
29
SAT
30
SUN
31
AM
PM

Medical School

School of Medicine, Seoul National University, Seoul, Korea

Specialty Training

Fellowship   Seoul National University Hospital
Samsung Medical Center
Residency   Seoul National University Hospital
Internship   Seoul National University Hospital

Clinical & Research Interests

Lung cancer, Head and neck cancer, breast cancer, gastric and colorectal cancer

Participation in Academic Societies
and Research

American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Korean Association of Clinical Oncology
Koran Cancer Association

Selected Publications

  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2019.08.001 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-50574-6 Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab Eun1, Y; Kim, IY; Sun, JM; Lee, J; Cha, HS; Koh, EM; Kim, H; Lee, J
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
    View PubMed